Skip to main content
Fig. 4 | BMC Anesthesiology

Fig. 4

From: Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

Fig. 4

Time course of liver function markers in patients with ARDS as stratified by antibiotic regime after admission to ICU. Group means are depicted as a bar chart with corresponding standard deviation. a Aspartate aminotransferase activity. The maximum values of each patient (pmax = 0.048) and the average values of the first 10 days (p1–10 < 0.001) and from days 11–20 (p11–20 = 0.031) were significantly different between moxifloxacin monotherapy (Moxi-Mono), moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In, there was no significant difference between during the last 10 days (p21–30 = 0.06). b Alanine aminotransferase activity. The maximum values of each patient (pmax = 0.003) and the average values in the first 10 days (p1–10 < 0.001) and from day 11–20 (p11–20 = 0.001) were significantly different between moxifloxacin monotherapy, moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In contrast, there was no significant difference in the last 10 days (p21–30 = 0.68). c Direct bilirubin concentration. The maximum values of each patient (pmax = 0.010) and the average values in the first 10 days (p1–10 < 0.001) were significantly different between moxifloxacin monotherapy (Moxi-Mono), moxifloxacin combination therapy (Moxi-Combi), and other regimens (Other). In contrast, there was no significant difference from day 11–20 (p11–20 = 0.091) and in the last 10 days (p21–30 = 0.64)

Back to article page